We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+16.39%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$5.55B
AUM Growth
+$896M
Cap. Flow
+$296M
Cap. Flow %
5.33%
Top 10 Hldgs %
41.26%
Holding
123
New
43
Increased
33
Reduced
14
Closed
29

Top Buys

Rank Stock Value
1
APD icon
Air Products & Chemicals
APD
+$135M
2
FISV
Fiserv Inc
FISV
+$129M
3
EL icon
Estee Lauder
EL
+$128M
4
AMZN icon
Amazon
AMZN
+$101M
5
MDT icon
Medtronic
MDT
+$81.8M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$104M
2
J icon
Jacobs Solutions
J
+$103M
3
MCK icon
McKesson
MCK
+$89M
4
CNC icon
Centene
CNC
+$87.9M
5
META icon
Meta Platforms (Facebook)
META
+$71M

Sector Composition

Rank Sector Weight
1 Technology 23.21%
2 Consumer Discretionary 19.67%
3 Healthcare 17.72%
4 Industrials 15.31%
5 Communication Services 10.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
51
Aurinia Pharmaceuticals
AUPH
$2.11B
$10.8M 0.2%
735,500
+579,800
+372% +$8.4M
TWND.U
52
DELISTED
Tailwind Acquisition Corp. Units, each consisting of one share of Class A common stock and one-half of one warrant
TWND.U
$10.1M 0.18%
+1,000,000
New +$10M
MRNS
53
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$10M 0.18%
779,725
+279,725
+56% +$2.41M
NVAX icon
54
Novavax
NVAX
$1.31B
$8.77M 0.16%
+80,914
New +$9.86M
SLNO
55
DELISTED
Soleno Therapeutics
SLNO
$8.1M 0.15%
215,117
+46,625
+28% +$1.36M
CLOVW
56
DELISTED
Clover Health Investments, Corp. Warrants
CLOVW
$7.88M 0.14%
2,042,469
+1,198,273
+142% +$3.75M
MRNA icon
57
PUT
Moderna
MRNA
$23.6B
$7.88M 0.14%
+111,400
New +$7.77M
LGND icon
58
Ligand Pharmaceuticals
LGND
$6.36B
$7.36M 0.13%
+123,774
New +$8.45M
SNPR.U
59
DELISTED
Tortoise Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-fourth of
SNPR.U
$7.07M 0.13%
+650,000
New +$7.03M
TPTX
60
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$6.93M 0.12%
79,331
+54,100
+214% +$3.77M
PRLD icon
61
Prelude Therapeutics
PRLD
$390M
$6.78M 0.12%
+225,000
New +$6.35M
CANO
62
DELISTED
Cano Health, Inc.
CANO
$5.46M 0.1%
+5,246
New +$5.48M
CHMA
63
DELISTED
Chiasma, Inc. Common Stock
CHMA
$4.48M 0.08%
1,041,556
+847,751
+437% +$4.06M
CHRS icon
64
Coherus Oncology
CHRS
$196M
$4.37M 0.08%
238,100
+56,800
+31% +$1.06M
FSDC
65
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$3.92M 0.07%
+350,000
New +$3.75M
KALV
66
DELISTED
KalVista Pharmaceuticals
KALV
$3.89M 0.07%
308,900
+61,900
+25% +$774K
SYRE icon
67
Spyre Therapeutics
SYRE
$9.25B
$3.75M 0.07%
21,164
+16,447
+349% +$3.04M
OPENW
68
DELISTED
Opendoor Technologies Inc Warrants expiring 12/18/2025
OPENW
$3.74M 0.07%
673,677
+269,011
+66% +$966K
KURA icon
69
Kura Oncology
KURA
$850M
$3.65M 0.07%
+119,000
New +$2.63M
KYMR icon
70
Kymera Therapeutics
KYMR
$8.94B
$3.56M 0.06%
+110,230
New +$3.36M
NAUT icon
71
Nautilus Biotechnolgy
NAUT
$115M
$3.25M 0.06%
+300,000
New +$3.2M
BMY.RT
72
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$2.93M 0.05%
1,300,968
-3,460,151
-73% -$9.88M
KDNY
73
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.77M 0.05%
228,256
+67,676
+42% +$907K
KZR
74
DELISTED
Kezar Life Sciences
KZR
$2.69M 0.05%
55,590
– –
CMLFU
75
DELISTED
CM Life Sciences, Inc. Unit
CMLFU
$2.67M 0.05%
+254,713
New +$2.68M
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Suvretta Capital Management held 123 positions worth $5.55B, up 19% from $4.65B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Suvretta Capital Management deployed $296M of net new capital in Q3 2020, opening 43 new positions and adding to 33 existing holdings. Its largest new stake was Air Products & Chemicals: 470,440 shares worth $140M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $71M trimmed.

  • Suvretta Capital Management's largest Q3 2020 buy was Air Products & Chemicals: 470,440 shares worth $140M.
  • Suvretta Capital Management added most to Amazon in Q3 2020, an estimated $101M increase.
  • Suvretta Capital Management's biggest Q3 2020 reduction was Meta Platforms (Facebook), cutting an estimated $71M.
  • Suvretta Capital Management fully exited Baxter International in Q3 2020, selling an estimated $104M.
  • Suvretta Capital Management's ten largest holdings make up 41% of its $5.55B portfolio in Q3 2020.
  • Suvretta Capital Management opened 43 new positions and closed 29 in Q3 2020.
  • Suvretta Capital Management's portfolio value rose 19% quarter-over-quarter to $5.55B.

Based on Suvretta Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.